ArticleAnnals of epidemiology2026
HIV disease progression following WHO treat all guideline adoption among people enrolled in HIV care in Central Africa: A multistate analysis.
Article in Annals of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionThe World Health Organization's Treat All guidelines, which eliminate eligibility thresholds for initiating antiretroviral therapy (ART) among people living with HIV, have been implemented by most countries. However, how Treat All relates to the clinical progression of HIV disease across stages remains less well characterized.
methodsWe applied a target trial-inspired design to examine the association between Treat All policy implementation and HIV disease progression in the Central Africa region of the International Epidemiology Databases to Evaluate AIDS (IeDEA). The analysis included individuals enrolled in HIV care between 2013 and 2019. Using continuous-time multistate models, we estimated transition-specific hazards across four WHO clinical stages (1: asymptomatic; 2: mild; 3: advanced; 4: severe) and death. Disease progression was compared between individuals enrolling after (n = 4607) versus before (n = 4439) Treat All adoption, with hazard ratios (HRs) estimated with and without covariate adjustment.
resultsAt enrollment, the distribution of WHO clinical stage in the Treat All cohort was 63.4% asymptomatic, 17.7% mild, 15.6% advanced, and 3.3% severe, compared with 59.1%, 18.3%, 19.0%, and 3.6%, respectively, in the pre-Treat All cohort. Treat All implementation was associated with lower hazards of disease progression for early-stage transitions. Specifically, reduced hazards were observed for transitions from stage 1 to stage 2 (adjusted HR [aHR] 0.64, 95% CI: 0.44-0.94) and from stage 1 directly to death (aHR 0.37, 95% CI: 0.17-0.81). Estimates for transitions originating from later disease stages were less precise, and no statistically significant differences were observed.
conclusionsEnrollment in HIV care following Treat All policy adoption was associated with reduced early-stage disease progression and mortality, suggesting more favorable disease-progression dynamics among individuals entering care in the Treat All era. These findings complement existing evidence on ART uptake and viral suppression and support the role of universal ART initiation in routine HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.